Indications for use:
To sows after weaning:
- Induction and synchronization of œstrus within 7 days following the treatment.
- Reduction of the weaning to oestrus interval in sows with late oestrus.
- Treatment of the seasonal anoestrus.
Composition:
Lyophilisate vial contains: Active substances : Equine serum gonadotrophin (PMSG) 2 000 IU, Gonadotrophin chorionic (HCG) 1 000 IU
Solvent vial contains: Excipients: Benzyl alcohol 375 mg
One ml of reconstituted solution contains: Active substances: Equine serum gonadotrophin (PMSG) - 80 IU, Gonadotrophin chorionic (HCG) - 40 IU; Excipients: Benzyl alcohol - 15 mg
Reconstituted solution for 1 dose of 5 ml contains: Active substances: Equine serum gonadotrophin (PMSG) - 400 IU, Gonadotrophin chorionic (HCG) - 200 IU; Excipients: Benzyl alcohol - 75 mg
Method of administration: Intramuscular use.
Dosage: 400 IU of equine serum gonadotrophin and 200 IU of chorionic gonadotrophin per animal, i.e. 5 ml of the reconstituted solution in one administration within 24 hours after the weaning.
Withdrawal period: Meat and offal: zero days.
Storage: This veterinary medicinal product does not require any special storage conditions. After reconstitution, store in a refrigerator (2°C - 8°C). Shelf-life after reconstitution according to directions: 28 days.
Packaging: Cardboard carton containing one vial of lyophilisate and one 25 ml vial solvent. Cardboard carton containing ten vials of lyophilisate and ten 25 ml vials solvent.
Once reconstituted the product contains five doses (5 ml/dose).
Contraindications
Do not administer to pregnant animals
Do not administer to animals with known hypersensitivity to the active substance.
Do not administer to sows with follicular cysts.
Adverse reactions (frequency and seriousness)
In rare cases anaphylactic shock is seen by repeated administration of PMSG and HCG, since PMSG and HCG are exogenous proteins for other species than equine and human and therefore can provoke an antigen-antibody reaction.
Special warnings
Dissolve the lyophilisate with a small quantity of solvent. Mix to obtain a homogenous solution. Transfer this solution into the vial that contains the rest of the solvent and mix until completely dissolved.
Treatment during the primary luteinised phase or in the middle of the cycle may increase the risk of ovarian cysts development. Do not adjust the dose. Increased doses do not increase the efficacy of the product.
Special precautions for use in animals
In case of anaphylactic shock, appropriatetreatment should be administered.
Special precautions to be taken by the person administering the medicinal products to animals
Care should be taken when handling the product to avoid self-injection. In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Wash hands after handling the product. The product can cause a slight skin irritation. When the product comes into contact with the skin, rinse immediately with plenty of water.
Pregnant women, women intending to become pregnant or whose pregnancy status is unknown, should not use the product due to the risk of unintended self injection. Studies in laboratory animals exhibited dose-dependent teratogenic effects after the administration of the combination HCG / PMSG.
People with known hypersentivity to gonadotrophins should avoid contact with the product.
A transient increase in progesterone level was observed following administration of 3 times the recommended dose, following the first oestrus.
An induration and a transient erythema have been observed at the injection site during the product administration with three times the therapeutic dose.
The daily administration of the therapeutic dose during 12 consecutive days can lead to the occurrence of ovarian cysts.
Do not administer in the same time with other veterinary medicinal products.